Trial
NCT03410056
Safety and Efficacy of Efavaleukin Alfa in Subjects With Active Rheumatoid Arthritis
Phase ITERMINATEDOPERATIONALConfidence: HIGH
Sponsor
Amgen
Collaborators
—
Condition
Rheumatoid Arthritis RA
Intervention
Efavaleukin alfa
Why stopped
Amgen made a business decision not to proceed with Phase 2.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2021-06-22